Danish Pharmacovigilance Update, 15 November 2012

17 January 2013

In this issue of Danish Pharmacovigilance Update:

  • Chlorhexidine and the risk of anaphylactic reaction (front page)
  • Consumption and safety of cholesterol-lowering medicines (p 2)
  • Benefits of NSAIDs continue to outweigh the potential risk of cardiovascular adverse reactions – however, the risk associated with diclofenac requires further investigation (p 3)
  • The European Medicines Agency, EMA, is reviewing data on medicines containing codeine, especially concerning the use in children (p 3)
  • Renal impairment in association with the use of ciclosporin (Sandimmun Neoral® and others) (p 4)
  • Persons initiated on treatment with Champix® (varenicline) for smoking cessation should be prescribed the recommended starter pack containing starting doses (p 5)
  • The Danish Health and Medicines Authority maintains influenza vaccine recommendation (p 5)
  • Danish Pharmacovigilance Update celebrates its 3rd anniversary (p 6)

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.